Author: GlobeNewswire

68% of patients receiving Kymriah in the ELARA trial experienced complete response, with an 86% overall response rate, along with…

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – May 27, 2022…

New York, NY, and Tel Aviv, ISRAEL, May 27, 2022 (GLOBE NEWSWIRE) — via NewMediaWire –Todos Medical, Ltd. (OTCQB: TOMDF), a…

BUFFALO, N.Y., May 27, 2022 (GLOBE NEWSWIRE) — 22nd Century Group, Inc. (Nasdaq: XXII), a leading agricultural biotechnology company dedicated…

TEL AVIV, Israel, May 27, 2022 (GLOBE NEWSWIRE) — SciSparc Ltd. (NASDAQ: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage…

IRVINE, Calif., May 27, 2022 (GLOBE NEWSWIRE) — Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet…

EDISON, N.J., May 27, 2022 (GLOBE NEWSWIRE) — In the press release issued earlier today by Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), we’ve…

New York, NY, and Tel Aviv, ISRAEL, May 27, 2022 (GLOBE NEWSWIRE) — via NewMediaWire –Todos Medical, Ltd. (OTCQB: TOMDF), a…

HALIFAX, Nova Scotia, May 27, 2022 (GLOBE NEWSWIRE) — Today, MedMira Inc. (MedMira) (TSXV: MIR) provides an update on its…

Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients…